Go Pro
NASDAQ:SEPN

Septerna Q4 2025 Earnings Report

Septerna logo
$38.51 +0.76 (+2.01%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$38.88 +0.37 (+0.95%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Septerna EPS Results

Actual EPS
-$0.24
Consensus EPS
-$0.23
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Septerna Revenue Results

Actual Revenue
N/A
Expected Revenue
$20.44 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Septerna Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Septerna's Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Septerna Earnings Headlines

Septerna to Participate in Upcoming Investor Conferences
Why I'm NOT Buying the SpaceX IPO (And What I'm Buying Instead)
Don't buy Nvidia... Not when the AI companies that will define the next decade are selling for pennies. You won't find them on any stock exchange. The big funds already know this... Their focus has shifted to a subsegment they call decentralized AI. They're launching tokens in the native markets. This is where coins list months before Coinbase, Kraken, or Robinhood… because raising from millions of investors beats begging a handful of funds. This is the world's first open venture capital market… a teacher in Ohio investing at the same stage as a billionaire in Singapore. Watch the free training on how to access the native markets (and buy potential AI unicorns before major exchange listings).tc pixel
Septerna names Rajiv Patni as CMO
See More Septerna Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Septerna? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Septerna and other key companies, straight to your email.

About Septerna

Septerna (NASDAQ:SEPN) is a clinical-stage biotechnology company focused on discovering and developing oral small-molecule medicines that target G protein-coupled receptors (GPCRs). GPCRs are a large class of cell-surface proteins involved in numerous biological processes and are established targets for therapies across a range of diseases.

The company uses its proprietary Native Orthosteric Ligand Discovery platform to study GPCRs in their native cellular environments and identify small-molecule compounds that can modulate these receptors. Septerna’s research and development efforts are directed toward potential treatments in areas including immunology, inflammation, metabolic disease and other conditions with significant unmet medical needs.

Septerna was founded to advance GPCR-directed drug discovery and became a publicly traded company on the Nasdaq under the symbol SEPN. The company is based in the United States and is focused primarily on advancing its internal discovery and clinical-stage pipeline rather than marketing approved products.

View Septerna Profile